Neurocrine Biosciences, Inc. (NBIX)
123.10
-14.34
(-10.43%)
USD |
NASDAQ |
Feb 12, 16:00
122.87
-0.23
(-0.19%)
After-Hours: 20:00
Neurocrine Biosciences Cash from Investing (Quarterly) : -52.90M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Pfizer Inc. | -- |
| Bio-Rad Laboratories, Inc. | -43.00M |
| Edwards Lifesciences Corp. | -- |
| Masimo Corp. | 282.30M |
| Marker Therapeutics, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 388.40M |
| Cash from Financing (Quarterly) | 37.30M |
| Free Cash Flow | 748.70M |
| Free Cash Flow Per Share (Quarterly) | 3.769 |
| Free Cash Flow to Equity (Quarterly) | 399.20M |
| Free Cash Flow to Firm (Quarterly) | 390.80M |
| Free Cash Flow Yield | 5.94% |